Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A small molecular compound for treating rheumatoid arthritis and its use

A rheumatoid and arthritis technology, applied in steroids, applications, organic chemistry, etc., can solve problems such as failure of secondary treatment, lack of safe and effective therapeutic drugs, and non-response of patients

Active Publication Date: 2021-05-07
LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of RA is very difficult, so far, there is still a lack of safe and effective therapeutic drugs
Modern medicine is mainly about anti-inflammation and reducing sequelae. Drugs such as TNFα inhibitors Etanercept, Infliximab and Adalimumab can reduce some objective symptom indicators such as swelling and tender joint counts to 50% in some RA patients. Its non-response, or the failure of the second treatment, an average of about 10% of patients discontinued each year

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A small molecular compound for treating rheumatoid arthritis and its use
  • A small molecular compound for treating rheumatoid arthritis and its use
  • A small molecular compound for treating rheumatoid arthritis and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0019] The CIA model of DBA / 1 mice was established. DBA / 1 female mice for 6-8 weeks, after adaptive feeding for 1 week, use bovine type II collagen and complete Freund's adjuvant (BCG concentration: 4 mg / ml), after complete emulsification, inject 100 μL intradermally into the back skin near the caudal vertebra (containing 100 μg of bovine type II collagen), after 42 days, the mouse lower limbs (below the ankle joint) or upper limbs (below the wrist joint) can appear obvious redness and swelling, and the incidence rate is about 90%. 42 days after the initial immunization of DBA / 1 mice, the model mice were randomly divided into two groups, the papaya saponin I group and the control group, with more than 10 mice in each group. In the papaya saponin I group, the papaya saponin I was dissolved in 0.5% carboxymethylcellulose sodium (CMC-Na) to prepare a suspension, and the control group was prepared with 0.5% CMC-Na. The dosage of papaya saponin I is 8mg / kg. Oral administration, o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a small molecular compound for treating rheumatoid arthritis, the active ingredient of which is papaya saponin I, and the concentration is 0.1-10 μM. The present invention has been proved by animal experiments that papaya saponin I can reduce joint damage and inflammatory infiltration area, bone mass defect and cartilage defect in mice with collagen-induced rheumatoid arthritis, reduce ankle joint inflammation damage, and can improve rheumatoid joints inflammation symptoms. The invention also discloses the application of the papaya saponin I in the preparation of rheumatoid arthritis medicine or health care product.

Description

technical field [0001] The invention relates to a small molecule compound for treating rheumatoid arthritis, and proposes the application of the compound in preparing various forms of medicines or health food for preventing and treating rheumatoid arthritis. Background technique [0002] The prior art discloses that rheumatoid arthritis (Rheumatoid Arthritis, RA) is a chronic, systemic, progressive, autoimmune disease characterized by widespread persistent synovitis and symmetrical, destructive joint Lesions are characteristic. The treatment of RA is very difficult, so far, there is still a lack of safe and effective drugs. Modern medicine is mainly about anti-inflammation and alleviating sequelae. Drugs such as TNFα inhibitors Etanercept, Infliximab and Adalimumab can reduce some objective symptom indicators such as swelling and tender joint counts to 50% in some RA patients, but many patients still have problems in initial treatment. Its non-response, or the failure of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07J71/00A61P19/02
CPCA23V2002/00A23L33/105C07J71/0005A23V2200/30A23V2250/21
Inventor 梁倩倩王拥军王琼徐浩施杞王腾腾齐晓凤贾庆运王怡茹刘洋王晓赟许崇卿刘利张利刘书芬李强赵永见
Owner LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com